| Characteristic |
|
2015
N=43 |
2016
N=38 |
2017
N=48 |
2018
N=25 |
2019
N=36 |
p-value
by Year |
p-value
by Cohort |
| Age, % (n) |
|
|
|
|
|
|
0.150 |
0.058 |
|
<50 |
30.2% (13) |
23.7% (9) |
14.6% (7) |
32.0% (8) |
38.9% (14) |
|
|
|
50-64 |
48.8% (21) |
47.4% (18) |
58.3% (28) |
28.0% (7) |
41.7% (15) |
|
|
|
≥65 |
20.9% (9) |
28.9% (11) |
27.1% (13) |
40.0% (10) |
19.4% (7) |
|
|
| Race, % (n) |
|
|
|
|
|
|
0.103 |
0.202 |
|
Asian |
32.6% (14) |
15.8% (6) |
16.7% (8) |
36.0% (9) |
36.1% (13) |
|
|
|
Hispanic |
14.0% (6) |
28.9% (11) |
35.4% (17) |
12.0% (3) |
30.6% (11) |
|
|
|
Caucasian
|
9.3% (4)
|
15.8% (6)
|
18.8% (9)
|
16.0% (4)
|
5.6% (2)
|
|
|
|
African American
|
44.2% (19)
|
39.5% (15)
|
29.2% (14)
|
36.0% (9)
|
27.8% (10)
|
|
|
| Clinical stage, % (n) |
|
|
|
|
|
|
0.032
|
0.108 |
|
1 |
51.2% (22) |
39.5% (15) |
60.4% (29) |
40.0% (10) |
33.3% (12) |
|
|
|
2 |
30.2% (13) |
39.5% (15) |
33.3% (16) |
32.0% (8) |
61.1% (22) |
|
|
|
3 |
11.6% (5) |
7.9% (3) |
2.1% (1) |
8.0% (2) |
0.0% (0) |
|
|
|
4 |
7.0% (3) |
13.2% (5) |
4.2% (2) |
20.0% (5) |
5.6% (2) |
|
|
| ER, % (n) |
|
|
|
|
|
|
0.151 |
0.415 |
|
Neg |
32.6% (14) |
13.2% (5) |
16.7% (8) |
20.0% (5) |
30.6% (11) |
|
|
|
Pos |
67.4% (29) |
86.8% (33) |
83.3% (40) |
80.0% (20) |
69.4% (25) |
|
|
| PR, % (n) |
|
|
|
|
|
|
0.906 |
0.692 |
|
Neg |
41.9% (18) |
36.8% (14) |
35.4% (17) |
36.0% (9) |
44.4% (16) |
|
|
|
Pos |
58.1% (25) |
63.2% (24) |
64.6% (31) |
64.0% (16) |
55.6% (20) |
|
|
| HER2, % (n) |
|
|
|
|
|
|
0.007
|
<0.001
|
|
Neg |
83.7% (36) |
89.5% (34) |
91.7% (44) |
64.0% (16) |
69.4% (25) |
|
|
|
Pos |
16.3% (7) |
10.5% (4) |
8.3% (4) |
36.0% (9) |
30.6% (11) |
|
|